Best Practices for Type 2 Diabetes Management: Update on Guidelines and New Treatment Advances

Vivian A. Fonseca, MD, FRCP, discusses best practices for the management of type 2 diabetes based on the latest guidelines and emerging treatment approaches.
Vivian A. Fonseca, MD, FRCP
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 4, 2016 Expiration: August 3, 2017

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize updated guideline recommendations for type 2 diabetes
  • Select guideline-recommended pharmacologic treatment(s) to achieve A1C goals while minimizing risk of adverse events such as hypoglycemia and weight gain
  • Devise a management plan for a patient with type 2 diabetes who is at high risk for hypoglycemia and who is not at target A1C goal
  • Apply tenets of shared decision making to the management of patients with type 2 diabetes

Information on this Educational Activity


As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.


Vivian A. Fonseca, MD, FRCP

Tullis-Tulane Alumni Chair in Diabetes
Professor of Medicine
Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Vivian Fonseca, MD: Research Support, Asahi, Bayer, Endo Barrier, Gilead Sciences; Consultant, Amgen, AstraZeneca, Eli Lilly, Janssen, Novo Nordisk, Sanofi-Aventis, Takeda.


Terrence Fagan

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD

Scientific Director

Megan Murphy, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Special Programs Committee (SPC)

The following SPC member who reviewed content for this activity reported the following relevant financial relationships:
Andrew Ahmann, MD: Research Support, DexCom, Lexicon Medtronic, Novo Nordisk, Sanofi Aventis; Consultant, Novo Nordisk, Eli Lilly, Janssen, Dexcom

The following SPC Committee members reported financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
E Michael Lewiecki, MD: Advisory Board, Amgen, Merck, Eli Lilly, Radius Health, Shire, and Alexion; Speaker, Shire; Research Support, Amgen, Eli Lilly, Merck
Alan Kelly, MD: Research Support, Novo Nordisk; Speaker, Novo Nordisk, Boehringer Ingelheim
Lisa Nachtigall, MD: Consultant, Pfizer, Chiasma
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim, Pfizer
Amy Rothberg, MD: Grant Support, Nestle

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships: Giuseppe Barbesino, MD; Natalie Cusano, MD; Joan Han, MD; Connie Newman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.


The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such off-label use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with diabetes


The goal of this activity is to update physicians on the latest guidelines for the management of type 2 diabetes, improve their confidence to select and advance treatment for an individualized management strategy, and keep up to date with emerging therapies that have the potential to positively affect care.

Physician Continuing Medical Education


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and Clinical Care Options. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians.


The Endocrine Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Creditâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions about content or obtaining CME credit, please contact the Endocrine Society at

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 04, 2016, through August 03, 2017:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CCO slides from Martin Abrahamson, MD, and Anne Peters, MD, on GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence

Martin J. Abrahamson, MD Anne Peters, MD Released: January 17, 2020

Slides from CCO and John Russell, MD, on GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence

John J. Russell, MD Released: December 23, 2019

CME: Type 2 diabetes management: Dr. Veronica K. Piziak on NPH, regular insulin, switching to avoid hypoglycemia/reduce CV risk in T2DM

Veronica K. Piziak, MD, PhD, FACP
Program Director
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: January 11, 2019 Expiration: January 10, 2020

Dr. Kenneth Cusi summarizes some of the most important data from recent studies in patients at high risk for NASH/NAFLD.

Kenneth Cusi, MD, FACP, FACE
Program Director
Released: December 13, 2018


Jointly provided by Endocrine Society and Clinical Care Options, LLC.

For questions about content or obtaining CME credit, please contact the Endocrine Society at

Supported by educational grants from
Merck & Co., Inc.
Novo Nordisk

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?